Cargando…

Heterogeneous EGFR Gene Copy Number Increase Is Common in Colorectal Cancer and Defines Response to Anti-EGFR Therapy

Anti-EGFR therapy is commonly used to treat colorectal cancer (CRC), although only a subset of patients benefit from the treatment. While KRAS mutation predicts non-responsiveness, positive predictive markers are not in clinical practice. We previously showed that immunohistochemistry (IHC)-guided E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ålgars, Annika, Avoranta, Tuulia, Österlund, Pia, Lintunen, Minnamaija, Sundström, Jari, Jokilehto, Terhi, Ristimäki, Ari, Ristamäki, Raija, Carpén, Olli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062406/ https://www.ncbi.nlm.nih.gov/pubmed/24940619 http://dx.doi.org/10.1371/journal.pone.0099590

Ejemplares similares

EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus
por: Birkman, Eva-Maria, et al.
Publicado: (2016)

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer
por: Ålgars, A, et al.
Publicado: (2011)

Reply: EGFR alterations and response to anti-EGFR therapy: is it a matter of gene amplification or gene copy number gain?
por: Ålgars, A, et al.
Publicado: (2012)

Gastric cancer: immunohistochemical classification of molecular subtypes and their association with clinicopathological characteristics
por: Birkman, Eva-Maria, et al.
Publicado: (2017)

Association of tumor-infiltrating T lymphocytes with intestinal-type gastric cancer molecular subtypes and outcome
por: Mansuri, Naziha, et al.
Publicado: (2020)

FHOD1 and FMNL1 formin proteins in intestinal gastric cancer: correlation with tumor-infiltrating T lymphocytes and molecular subtypes
por: Mansuri, Naziha, et al.
Publicado: (2021)

Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer
por: Birkman, Eva‐Maria, et al.
Publicado: (2018)

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer
por: Osterlund, Emerik, et al.
Publicado: (2022)

Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study
por: Uutela, Aki, et al.
Publicado: (2022)

Resectability and resection rates of colorectal liver metastases according to RAS and BRAF mutational status: prospective study
por: Uutela, Aki, et al.
Publicado: (2022)

Short-course preoperative radiotherapy increases pelvic fracture risk in rectal cancer
por: Vesa, Väliaho, et al.
Publicado: (2023)

Resectability, Resections, Survival Outcomes, and Quality of Life in Older Adult Patients with Metastatic Colorectal Cancer (the RAXO-Study)
por: Lehtomäki, Kaisa, et al.
Publicado: (2023)

Protein phosphatase methylesterase‐1 (PME‐1) expression predicts a favorable clinical outcome in colorectal cancer
por: Kaur, Amanpreet, et al.
Publicado: (2015)

Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study
por: Lehtomäki, Kaisa, et al.
Publicado: (2022)

Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study
por: Osterlund, Pia, et al.
Publicado: (2021)

EGFR alterations and response to anti-EGFR therapy: is it a matter of gene amplification or gene copy number gain?
por: Sesboüé, R, et al.
Publicado: (2012)

Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
por: Lee, H J, et al.
Publicado: (2015)

Ezrin expression combined with MSI status in prognostication of stage II colorectal cancer
por: Slik, Khadija, et al.
Publicado: (2017)

Defining EGFR amplification status for clinical trial inclusion
por: French, Pim J, et al.
Publicado: (2019)

Identification of prognostic values defined by copy number variation, mRNA and protein expression of LANCL2 and EGFR in glioblastoma patients
por: Zhao, Hua-fu, et al.
Publicado: (2021)

Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas
por: Liang, Zhiyong, et al.
Publicado: (2010)

Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC
por: Gaber, Rania, et al.
Publicado: (2014)

The role of HIF prolyl hydroxylases in tumour growth
por: Jokilehto, Terhi, et al.
Publicado: (2010)

Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients
por: Pugh, Trevor J, et al.
Publicado: (2007)

Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC
por: Wei, Jiacong, et al.
Publicado: (2021)

EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis
por: Yang, Zu-Yao, et al.
Publicado: (2012)

The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
por: Chau, Nicole G, et al.
Publicado: (2011)

Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing
por: Holm, Matilda, et al.
Publicado: (2020)

The influence of tumor heterogeneity on sensitivity of EGFR-mutant lung adenocarcinoma cells to EGFR-TKIs
por: Sun, Li, et al.
Publicado: (2019)

High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR
por: Wang, Fang, et al.
Publicado: (2013)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Phosphoproteomics-Based Modeling Defines the Regulatory Mechanism Underlying Aberrant EGFR Signaling
por: Tasaki, Shinya, et al.
Publicado: (2010)

A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors
por: Gelfo, Valerio, et al.
Publicado: (2016)

The EGFR-TMEM167A-p53 Axis Defines the Aggressiveness of Gliomas
por: Segura-Collar, Berta, et al.
Publicado: (2020)

Epidermal Growth Factor (EGFR) copy number aberrations in esophageal and gastro-esophageal junctional carcinoma
por: Dahle-Smith, Åsa, et al.
Publicado: (2015)

Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma
por: Muñoz-Hidalgo, Lisandra, et al.
Publicado: (2019)

The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab
por: Demurtas, Laura, et al.
Publicado: (2017)

Understanding EGFR heterogeneity in lung cancer
por: Passaro, Antonio, et al.
Publicado: (2020)

Brk/PTK6 Sustains Activated EGFR Signaling through Inhibiting EGFR Degradation and Transactivating EGFR
por: Li, X, et al.
Publicado: (2012)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3mj54eeliqom1no3ddbnr4een0